S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
This Stock Could Go Up 66% or More. (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
This Stock Could Go Up 66% or More. (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
This Stock Could Go Up 66% or More. (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
This Stock Could Go Up 66% or More. (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:TXG

10x Genomics (TXG) Stock Forecast, Price & News

$41.35
-0.56 (-1.34%)
(As of 09/22/2023 ET)
Compare
Today's Range
$41.25
$42.50
50-Day Range
$41.35
$62.98
52-Week Range
$23.81
$63.57
Volume
1.05 million shs
Average Volume
909,323 shs
Market Capitalization
$4.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.73

10x Genomics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
42.0% Upside
$58.73 Price Target
Short Interest
Healthy
4.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
-0.14mentions of 10x Genomics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$4.68 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.76) to ($1.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

194th out of 963 stocks

Analytical Instruments Industry

11th out of 27 stocks


TXG stock logo

About 10x Genomics (NASDAQ:TXG) Stock

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Price History

TXG Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
10x Genomics Surpasses 100 Xenium Analyzer Shipments
Barclays Keeps Their Buy Rating on 10x Genomics (TXG)
Where 10x Genomics Stands With Analysts
See More Headlines
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

TXG Company Calendar

Last Earnings
8/03/2023
Today
9/24/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TXG
Fax
N/A
Employees
1,243
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$58.73
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+42.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-166,000,000.00
Pretax Margin
-29.36%

Debt

Sales & Book Value

Annual Sales
$516.41 million
Book Value
$6.99 per share

Miscellaneous

Free Float
104,913,000
Market Cap
$4.86 billion
Optionable
Optionable
Beta
1.77
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Serge Saxonov Ph.D. (Age 46)
    Co-Founder, CEO & Director
    Comp: $837.68k
  • Dr. Benjamin J. Hindson Ph.D. (Age 48)
    Co-Founder, Pres, Chief Scientific Officer & Director
    Comp: $615.96k
  • Mr. Justin J. McAnearMr. Justin J. McAnear (Age 47)
    Chief Financial Officer
    Comp: $535.91k
  • Mr. Eric S. Whitaker Esq. (Age 56)
    Chief Legal Officer
    Comp: $558.97k
  • Mr. James L. Wilbur Ph.D. (Age 58)
    Chief Commercial Officer
    Comp: $390.78k
  • Mr. Michael Schnall-Levin
    Founding Scientist & CTO
  • Ms. Cassie Corneau
    Mang. of Investor Relations and Strategic Fin.
  • Ms. Rebecca Port
    Chief People Officer
  • Mr. James Bryant
    Director of Legal
  • Mr. Nikhil Rao
    Director of Product Management













TXG Stock - Frequently Asked Questions

Should I buy or sell 10x Genomics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TXG shares.
View TXG analyst ratings
or view top-rated stocks.

What is 10x Genomics' stock price forecast for 2023?

9 equities research analysts have issued 1 year target prices for 10x Genomics' stock. Their TXG share price forecasts range from $25.00 to $75.00. On average, they expect the company's stock price to reach $58.73 in the next year. This suggests a possible upside of 42.0% from the stock's current price.
View analysts price targets for TXG
or view top-rated stocks among Wall Street analysts.

How have TXG shares performed in 2023?

10x Genomics' stock was trading at $36.44 on January 1st, 2023. Since then, TXG stock has increased by 13.5% and is now trading at $41.35.
View the best growth stocks for 2023 here
.

When is 10x Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our TXG earnings forecast
.

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) issued its earnings results on Thursday, August, 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.14. The business earned $146.82 million during the quarter, compared to analyst estimates of $139.97 million. 10x Genomics had a negative net margin of 30.31% and a negative trailing twelve-month return on equity of 21.69%. The business's revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.57) EPS.

What guidance has 10x Genomics issued on next quarter's earnings?

10x Genomics updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $600.00 million-$620.00 million, compared to the consensus revenue estimate of $600.73 million.

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

(TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

What is 10x Genomics' stock symbol?

10x Genomics trades on the NASDAQ under the ticker symbol "TXG."

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (7.32%), BlackRock Inc. (4.65%), Sands Capital Management LLC (3.55%), ARK Investment Management LLC (2.68%), Brown Capital Management LLC (2.65%) and SRS Investment Management LLC (1.87%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends
.

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 10x Genomics' stock price today?

One share of TXG stock can currently be purchased for approximately $41.35.

How much money does 10x Genomics make?

10x Genomics (NASDAQ:TXG) has a market capitalization of $4.86 billion and generates $516.41 million in revenue each year. The company earns $-166,000,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How many employees does 10x Genomics have?

The company employs 1,243 workers across the globe.

How can I contact 10x Genomics?

10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The official website for the company is www.10xgenomics.com. The company can be reached via phone at 925-401-7300 or via email at investors@10xgenomics.com.

This page (NASDAQ:TXG) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -